# **Table of Contents**

# State/Territory Name: Arizona

## State Plan Amendment (SPA) #: 22-0003

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, Maryland 21244-1850



June 24, 2022

Jami Snyder, Director Arizona Health Care Cost Containment System 801 East Jefferson Street Phoenix, AZ 85034

Re: Arizona State Plan Amendment (SPA) 22-0003

Dear Ms. Snyder:

The Centers for Medicare & Medicaid Services (CMS) reviewed the proposed Medicaid State Plan Amendment (SPA) submitted under transmittal number (TN) 22-0003. This amendment proposes to assure the state's coverage of COVID-19 testing, as required by section 1905(a)(4)(F) of the Social Security Act (Act).

Pursuant to section 1135(b)(5) of the Act, for the period of the public health emergency, CMS is modifying the requirement at 42 C.F.R. §430.20 that the state submit SPAs related to the COVID-19 public health emergency by the final day of the quarter, to obtain a SPA effective date during the quarter, enabling SPAs submitted after the last day of the quarter to have an effective date in a previous quarter, but no earlier than the effective date of the public health emergency.

Please note that the establishment of or changes to any payment methodologies approved to take effect after the end of the Public Health Emergency (PHE) in this SPA must meet the public notice requirements of 42 CFR 447.205.

CMS conducted our review of your submittal according to statutory requirements in Title XIX of the Act and implementing regulations. This letter is to inform you that Arizona's Medicaid SPA Transmittal Number 22-0003 is approved effective March 11, 2021

If you have any questions, please contact Brian Zolynas at 415-744-3601 or via email at Brian.Zolynas@cms.hhs.gov.

Sincerely,

Alissa M. Deboy -S Date: 2022.06.24 08:06:40 -04'00'

Alissa Mooney DeBoy On Behalf of Anne Marie Costello, Deputy Director Center for Medicaid and CHIP Services

Enclosures

CENTERS FOR MEDICARE & MEDICAID SERVICES	OMB No. 0938-0193
TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	
	3. PROGRAM IDENTIFICATION: TITLE <u>19</u> OF THE SOCIALSECURITY ACT
TO: CENTER DIRECTOR CENTERS FOR MEDICAID & CHIP SERVICES	4. PROPOSED EFFECTIVE DATE March 11, 2021
5. FEDERAL STATUTE/REGULATION CITATION Section 1905(a)(4)(F) of the Social Security Act	6. FEDERAL BUDGET IMPACT (Amounts in WHOLE dollars) a. FFY <u>2021</u> \$ <u>0</u> b. FFY: <u>2022</u> \$ <u>0</u>
7. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT Attachment 7.7-B	8. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable)
Page 1-3	NEW
10. GOVERNOR'S REVIEW (Check One) GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	OTHER, AS SPECIFIED:
11. SIGNATURE OF STATE AGENCY OFFICIAL	15. RETURN TO
	Dana Flannery 801 E, Jefferson, MD#4200 Phoenix, AZ 85034
12. TYPED NAME Dana Flannery	
13. TITLE Assistant Director 14. DATE SUBMITTED: April 7, 2022	
FOR CMS	USE ONLY
April 7, 2022	17. DATE APPROVED June 24, 2022
PLAN APPROVED - O	NE COPY ATTACHED
18. EFFECTIVE DATE OF APPROVED MATERIAL March 11, 2021	19. SIGNATURE OF APPROVING STATIMAL Deboy -S Deboy -S Date: 2022.06 24 08:07:01 -04'00'
20. TYPED NAME OF APPROVING OFFICIAL	21. TITLE OF APPROVING OFFICIAL
Alissa Mooney DeBoy	on Behalf of Anne Marie Costello, Deputy Director, CMCS
22. REMARKS	

### COVID-19 Testing at section 1905(a)(4)(F) of the Social Security Act

During the period starting March 11, 2021 and ending on the last day of the first calendar quarter that begins one year after the last day of the emergency period described in section 1135(g)(1)(B) of the Social Security Act (the Act):

#### <u>Coverage</u>

\_X\_\_ The states assures coverage of COVID-19 testing consistent with the Centers for Disease Control and Prevention (CDC) definitions of diagnostic and screening testing for COVID-19 and its recommendations for who should receive diagnostic and screening tests for COVID-19.

\_X\_\_ The state assures that such coverage:

- 1. Includes all types of FDA authorized COVID-19 tests;
- 2. Is provided to all categorically needy eligibility groups covered by the state that receive full Medicaid benefits;
- 3. Is provided to the optional COVID-19 group if applicable; and
- 4. Is provided to beneficiaries without cost sharing pursuant to section 1916(a)(2)(l) and 1916A(b)(3)(B)(xiii) of the Act; reimbursement to qualified providers for such coverage is not reduced by any cost sharing that would otherwise be applicable under the state plan.

Please describe any limits on amount, duration or scope of COVID-19 testing consistent with 42 CFR 440.230(b).

\_X\_\_ Applies to the state's approved Alternative Benefit Plans, without any deduction, cost sharing, or similar charge, pursuant to section 1937(b)(8)(B) of the Act.

\_X\_\_The state assures compliance with the HHS COVID-19 PREP Act declarations and authorizations, including all of the amendments to the declaration.

Additional Information (Optional):

### <u>Reimbursement</u>

\_\_\_X\_\_ The state assures that it has established state plan rates for COVID-19 testing consistent with the CDC definitions of diagnostic and screening testing for COVID-19 and its recommendations for who should receive diagnostic and screening tests for COVID-19.

List references to Medicaid state plan payment methodologies that describe the rates for COVID-19 testing for each applicable Medicaid benefit:

- State Plan Attachment 4.19-B, page 1a: Outpatient Hospital Benefit
- State Plan Attachment 4.19-B, page 5c: Testing under all other non-institutional benefits
- Attachment 4.19-B, page 7-7(a): IHS/638 Facilities When provided as part of a clinic visit, testing at IHS/638 Facilities is paid at the Outpatient All Inclusive Rate (AIR).
- Attachment 4.19-B, page 3a-5: FQHCs/RHCs When provided as part of a clinic visit, testing at FQHCs/RHCs is paid at the PPS rate.

\_\_\_\_\_ The state is establishing rates for COVID-19 testing pursuant to pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act.

\_\_\_\_\_ The state's rates for COVID-19 testing are consistent with Medicare rates for testing, including any future Medicare updates at the:

\_\_\_\_\_ Medicare national average, OR

\_\_\_\_\_ Associated geographically adjusted rate.

\_\_\_\_\_ The state is establishing a state specific fee schedule for COVID-19 testing pursuant to sections 1905(a)(4)(F) and 1902(a)(30)(A) of the Act.

The state's rate is as follows and the state's fee schedule is published in the following location:

\_\_\_\_\_ The state's fee schedule is the same for all governmental and private providers.

\_\_\_\_\_ The below listed providers are paid differently from the above rate schedules and payment to these providers for COVID-19 testing is described under the benefit payment methodology applicable to the provider type:

Additional Information (Optional):

\_\_\_\_\_The payment methodologies for COVID-19 testing for providers listed above are described below:

**PRA Disclosure Statement** Under the Privacy Act of 1974 any personally identifying information obtained will be kept private to the extent of the law. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid Office of Management and Budget (OMB) control number. The OMB control number for this project is 0938-1148 (CMS-10398 # 75). Public burden for all of the collection of information requirements under this control number is estimated to take up to 1 hour per response. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to CMS, 7500 Security Boulevard, Attn: Paperwork Reduction Act Reports Clearance Officer, Mail Stop C4-26-05, Baltimore, Maryland 21244-1850.